Cardiorenal Syndrome Market Size (7MM) is Expected to Grow Steadily During the Forecast Period of 2025-2034 | DelveInsight

DelveInsight's "Cardiorenal Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Cardiorenal Syndrome, historical and forecasted epidemiology, and the Cardiorenal Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Explore the intricate details of the Cardiorenal Syndrome Market Report @ https://www.delveinsight.com/report-store/cardiorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Cardiorenal Syndrome Market Report
• The cardiorenal syndrome market is projected to grow steadily during the forecast period (2025-2034), driven by emerging therapies, advanced diagnostics, rising disease awareness, and an increasing number of reported cases.
• Rising cases of cardiorenal syndrome are mainly attributed to the growing burden of diabetes, hypertension, and heart failure, fueling a vicious cycle between the heart and kidneys.
• In the US, over 1 in 10 Americans have diabetes, with type 2 diabetes comprising approximately 90-95% of all cases, and more than 1 in 7 adults are living with CKD.
• In the US, the prevalence of CKD among individuals with heart failure is approximately 27.7%, while hypertension is highly prevalent among CKD patients, with estimates ranging from 60-90%.
• In Spain, the estimated prevalence of CKD in patients with type 2 diabetes mellitus was 27.9%.
• In Japan, the prevalence of heart failure was reported to be 2.2-3.7% among patients aged 74 years or younger, and CKD has been found to affect approximately 13% of the population.
• In 2024, the United States held a significant share of the overall 7MM cardiorenal syndrome market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of available treatments.
• The Cardiorenal Syndrome Companies include Bayer HealthCare Pharmaceuticals, Novo Nordisk, AstraZeneca, Eli Lilly, Iperboreal Pharma, and others.
• Promising Cardiorenal Syndrome Therapies include Balcinrenone/dapagliflozin and PolyCore (Polydextrin, L-Carnitine, D-xylitol), among others.

Get a Free sample for the Cardiorenal Syndrome Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/cardiorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Cardiorenal Syndrome?
Cardiorenal syndrome is a multifactorial disorder characterized by bidirectional organ dysfunction, where impairment in cardiac or renal function leads to secondary dysfunction in the other organ. It involves complex interrelated mechanisms including neurohormonal activation, altered hemodynamics, endothelial dysfunction, and systemic inflammation. It can develop acutely or chronically and is commonly associated with conditions such as heart failure, CKD, hypertension, and diabetes, underscoring the need for integrated, multidisciplinary management approaches. Presentation may include fatigue, dyspnea, reduced urine output, peripheral and abdominal edema, cognitive disturbances, and arrhythmic sensations such as palpitations, often indicating disease progression.
There is no definitive test for diagnosing cardiorenal syndrome; diagnosis is based on clinical judgment through careful evaluation of fluid status and organ function, correlating multiple clinical parameters to differentiate it from isolated cardiac or renal conditions.

Cardiorenal Syndrome Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Selected Indications for Cardiorenal Syndrome
• Total Diagnosed Prevalent Cases of Selected Indications for Cardiorenal Syndrome
• Total Diagnosed Prevalent Cases of Cardiorenal Syndrome
• Treated Cases of Cardiorenal Syndrome

Download the report to understand which factors are driving Cardiorenal Syndrome epidemiology trends @ https://www.delveinsight.com/report-store/cardiorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Cardiorenal Syndrome Approved Therapies
• KERENDIA (finerenone): Bayer HealthCare Pharmaceuticals
KERENDIA is an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA) that selectively targets mineralocorticoid receptor overactivation in the heart and kidneys, mitigating inflammation and fibrosis in chronic conditions. Approved in the US, EU, and Japan, it is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and heart failure hospitalization in adults with CKD associated with T2DM, and to lower the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure and LVEF = 40%.

• OZEMPIC (semaglutide): Novo Nordisk
OZEMPIC is a GLP-1 receptor agonist approved in the US, EU, and Japan for the management of type 2 diabetes, indicated as an adjunct to diet and exercise to improve glycemic control and to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease. It also slows the progression of kidney disease, helping lower the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD.

• FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
Dapagliflozin is a first-in-class, oral SGLT2 inhibitor approved for treating type 2 diabetes, heart failure (HFrEF and HFpEF), and CKD, offering broad cardiorenal protection by targeting the interlinked functions of the heart, kidneys, and pancreas. Approved in the US, EU, and Japan, it is indicated to treat heart failure across all ejection fractions, chronic kidney disease (with or without type 2 diabetes), and to improve glycemic control in adults and children (=10 years) with type 2 diabetes, while reducing risks of CV death, HF hospitalization, and renal decline.

Cardiorenal Syndrome Pipeline Analysis
• Balcinrenone/dapagliflozin: AstraZeneca
Balcinrenone/dapagliflozin is an investigational oral small-molecule combination therapy pairing a mineralocorticoid receptor (MR) modulator with an SGLT2 inhibitor, being evaluated for its potential to improve outcomes in patients with heart failure and coexisting CKD. It is currently being evaluated in the Phase III BalanceD-HF trial in patients with heart failure and impaired kidney function, with AstraZeneca expected to release results after 2026.

• PolyCore (Polydextrin, L-Carnitine, D-xylitol): Iperboreal Pharma
PolyCore is an innovative osmo-metabolic and colloidal-based ultrafiltration solution designed for continuous ambulatory peritoneal dialysis (CAPD). Engineered for high biocompatibility, it minimizes intra-peritoneal glucose exposure while incorporating bioactive agents that help preserve peritoneal membrane integrity. It is currently being evaluated in a Phase I/II trial for its potential to prevent heart failure exacerbation in this high-risk population.

Cardiorenal Syndrome Companies
Bayer HealthCare Pharmaceuticals, Novo Nordisk, AstraZeneca, Eli Lilly, Iperboreal Pharma, and others
Discover more about therapies set to grab major Cardiorenal Syndrome market share @ https://www.delveinsight.com/sample-request/cardiorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Cardiorenal Syndrome Market Outlook
Cardiorenal syndrome management requires timely, severity-based intervention. Mild cases may respond to oral diuretics and neurohormonal agents, while advanced cases often necessitate IV diuretics, inotropes, or renal replacement therapy, with treatment guided by hemodynamic status, biomarkers, and organ function. Management involves a combination of pharmacologic and device-based therapies tailored to individual needs, including diuretics, beta-blockers, ACE inhibitors, ARBs, ARNI, mineralocorticoid receptor antagonists, renin-angiotensin system blockers, and inotropes. In advanced cases, interventions such as ultrafiltration, dialysis, implantable devices (ICD, LVAD, CRT), or organ transplantation (heart or kidney) may be required to stabilize function and improve outcomes.
Despite advances in heart failure and CKD management, cardiorenal syndrome continues to face key unmet needs due to the lack of therapies that effectively address both cardiac and renal dysfunction simultaneously, with current treatment options often suboptimal and limited data on their impact across dual-organ failure. The emerging pipeline, including candidates such as PolyCore and the balcinrenone/dapagliflozin combination, aims to address these existing treatment gaps and offer novel approaches in this clinically complex and underserved area. LY3437943, a biologic triagonist developed by Eli Lilly targeting the GIP, GLP-1, and glucagon receptors, is also being investigated for its potential to reduce cardiovascular and renal complications in patients with obesity.
The market's growth is further expected to be driven by the rising prevalence population, technological advancements in diagnostics and monitoring tools, growing focus on personalized medicine, and increasing healthcare expenditure and infrastructure over the forecast period.

Scope of the Cardiorenal Syndrome Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM (US, EU4 [Germany, France, Italy, and Spain], UK, and Japan)
• Cardiorenal Syndrome Companies: Bayer HealthCare Pharmaceuticals, Novo Nordisk, AstraZeneca, Eli Lilly, Iperboreal Pharma, and others
• Cardiorenal Syndrome Therapies: KERENDIA (finerenone), OZEMPIC (semaglutide), FARXIGA/FORXIGA (dapagliflozin), and others
• Cardiorenal Syndrome Therapeutic Assessment: Cardiorenal Syndrome current marketed and emerging therapies
• Cardiorenal Syndrome Market Dynamics: Cardiorenal Syndrome market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Cardiorenal Syndrome Unmet Needs, KOL's views, Analyst's views, Cardiorenal Syndrome Market Access and Reimbursement

To know more about Cardiorenal Syndrome companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/cardiorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Cardiorenal Syndrome: Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.